{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T19:01:41Z","timestamp":1774551701224,"version":"3.50.1"},"reference-count":31,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T00:00:00Z","timestamp":1752624000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004320","name":"Shiraz University of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004320","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec038\">\n<jats:title>Background<\/jats:title>\n<jats:p>Despite the wide variety of antiplatelet regimens and durations, the optimal treatment approach for chronic coronary syndrome (CCS) patients remains a subject of ongoing debate. While current guidelines recommend dual antiplatelet therapy (DAPT) with aspirin and clopidogrel, the development of drug-eluting stents (DES) and more potent agents has sparked interest in shorter DAPT regimens, followed by P2Y12 inhibitor monotherapy, as a potential alternative. Recent trials and meta-analyses have shown that this approach may provide similar protection against thrombotic events with reduced bleeding risk. Despite promising data, the safety and efficacy of Ticagrelor monotherapy specifically in CCS patients have not been rigorously tested in randomized trials.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec039\">\n<jats:title>Methods<\/jats:title>\n<jats:p>TICALONE is a non-inferiority, two-arm, double-blinded, randomized controlled clinical trial designed to evaluate the safety and efficacy of ticagrelor monotherapy compared to DAPT in CCS patients following PCI. Eligible patients undergoing PCI with drug-eluting stents will be randomly assigned to receive either conventional DAPT (aspirin and clopidogrel) or ticagrelor monotherapy for six months. Follow-up visits will be conducted at 1, 3, 6, and 12 months post-PCI to assess efficacy and safety endpoints. The primary efficacy endpoint is a composite endpoint of cardiac death, myocardial infarction, stroke, stent thrombosis, and the need for revascularization. The primary safety endpoint is the occurrence of Bleeding Academic Research Consortium (BARC) type 3 or 5 bleeding events. The secondary endpoints include components of the primary efficacy endpoint, any bleeding event (BARC type 1\u20135), and all-cause mortality. Ancillary endpoints are other adverse events including dyspnea, drug adherence, and reaction. All endpoints will be monitored by a Data Safety Monitoring Board (DSMB) and Trial Management Committee (TMC). Statistical analysis and reporting of trial results will follow the estimand framework. Kaplan-Meier estimates will be used to assess event rates, while the log-rank test and Cox regression analysis will be employed to compare safety and efficacy outcomes between the groups.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec040\">\n<jats:title>Discussion<\/jats:title>\n<jats:p>This trial may serve as a crucial step toward eliminating aspirin from post-PCI regimens, specifically in CCS patients. By comparing the safety and efficacy of Ticagrelor monotherapy with the conventional DAPT regimen and addressing potential risks of aspirin-free therapy and adverse events like dyspnea, this study could offer valuable insights into the possibility of P2Y12 monotherapy\u2019s safe adoption in this population.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec041\">\n<jats:title>Trial registration<\/jats:title>\n<jats:p>TICALONE is registered at <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/\" xlink:type=\"simple\">https:\/\/clinicaltrials.gov\/<\/jats:ext-link> with the identifier NCT06509893.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0325663","type":"journal-article","created":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T17:36:42Z","timestamp":1752687402000},"page":"e0325663","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Rationale and design of randomized non-inferiority clinical trial to compare the safety and efficacy of ticagrelor monotherapy with dual antiplatelet therapy in chronic coronary syndrome patients post percutaneous coronary intervention (TICALONE-TAHA10 Protocol)"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-3920-8640","authenticated-orcid":true,"given":"Seyed Alireza","family":"Mirhosseini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammadreza","family":"Akbari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davar","family":"Aldavood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hooyar","family":"Zarifkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4133-4870","authenticated-orcid":true,"given":"Armin","family":"Attar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8909-897X","authenticated-orcid":true,"given":"Javad","family":"Kojuri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2025,7,16]]},"reference":[{"issue":"9","key":"pone.0325663.ref001","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.jacc.2023.04.003","article-title":"2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines","volume":"82","author":"SS Virani","year":"2023","journal-title":"J Am College of Cardiol"},{"key":"pone.0325663.ref002","article-title":"2024 ESC Guidelines for the management of chronic coronary syndromes: Developed by the task force for the management of chronic coronary syndromes of the European Society of Cardiology (ESC) endorsed by the European Association for Cardio-Thoracic Surgery (EACTS)","author":"C Vrints","year":"2024","journal-title":"European Heart J"},{"issue":"17","key":"pone.0325663.ref003","doi-asserted-by":"crossref","DOI":"10.4244\/EIJ-D-21-00904","article-title":"Antiplatelet therapy after percutaneous coronary intervention","volume":"17","author":"DJ Angiolillo","year":"2022","journal-title":"EuroIntervention"},{"issue":"2","key":"pone.0325663.ref004","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1093\/ehjcvp\/pvaa001","article-title":"Very short vs. long dual antiplatelet therapy after second generation drug-eluting stents in 35 785 patients undergoing percutaneous coronary interventions: a meta-analysis of randomized controlled trials","volume":"7","author":"S Benenati","year":"2021","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"6","key":"pone.0325663.ref005","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1161\/CIRCULATIONAHA.120.046251","article-title":"The safety and efficacy of aspirin discontinuation on a background of a P2Y12 inhibitor in patients after percutaneous coronary intervention: a systematic review and meta-analysis","volume":"142","author":"ML O\u2019Donoghue","year":"2020","journal-title":"Circulation"},{"issue":"8","key":"pone.0325663.ref006","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/s41569-018-0049-1","article-title":"Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention","volume":"15","author":"D Capodanno","year":"2018","journal-title":"Nat Rev Cardiol"},{"issue":"8","key":"pone.0325663.ref007","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1161\/CIRCULATIONAHA.123.066943","article-title":"Stopping aspirin within 1 month after stenting for ticagrelor monotherapy in acute coronary syndrome: the T-PASS randomized noninferiority trial","volume":"149","author":"S-J Hong","year":"2024","journal-title":"Circulation"},{"issue":"21","key":"pone.0325663.ref008","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1056\/NEJMoa1908419","article-title":"Ticagrelor with or without aspirin in high-risk patients after PCI","volume":"381","author":"R Mehran","year":"2019","journal-title":"N Engl J Med"},{"issue":"24","key":"pone.0325663.ref009","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1001\/jama.2019.8145","article-title":"Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: the STOPDAPT-2 randomized clinical trial","volume":"321","author":"H Watanabe","year":"2019","journal-title":"JAMA"},{"issue":"10439","key":"pone.0325663.ref010","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1016\/S0140-6736(24)00473-2","article-title":"Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after percutaneous coronary intervention in patients with acute coronary syndromes (ULTIMATE-DAPT): a randomised, placebo-controlled, double-blind clinical trial","volume":"403","author":"Z Ge","year":"2024","journal-title":"Lancet"},{"issue":"23","key":"pone.0325663.ref011","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1001\/jama.2020.7580","article-title":"Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome: the TICO randomized clinical trial","volume":"323","author":"B-K Kim","year":"2020","journal-title":"JAMA"},{"issue":"6","key":"pone.0325663.ref012","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1253\/circj.CJ-23-0051","article-title":"Prasugrel monotherapy after percutaneous coronary intervention with biodegradable-polymer platinum-chromium everolimus eluting stent for japanese patients with chronic coronary syndrome (ASET-JAPAN)","volume":"87","author":"T Muramatsu","year":"2023","journal-title":"Circ J"},{"issue":"19","key":"pone.0325663.ref013","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1016\/j.jcin.2020.06.023","article-title":"Aspirin-free prasugrel monotherapy following coronary artery stenting in patients with stable CAD: the ASET pilot study","volume":"13","author":"N Kogame","year":"2020","journal-title":"JACC Cardiovasc Interv"},{"issue":"8","key":"pone.0325663.ref014","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1161\/CIRCULATIONAHA.123.066720","article-title":"An aspirin-free versus dual antiplatelet strategy for coronary stenting: STOPDAPT-3 randomized trial","volume":"149","author":"M Natsuaki","year":"2024","journal-title":"Circulation"},{"issue":"6","key":"pone.0325663.ref015","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1253\/circj.CJ-23-0051","article-title":"Prasugrel monotherapy after percutaneous coronary intervention with biodegradable-polymer platinum-chromium everolimus eluting stent for japanese patients with chronic coronary syndrome (ASET-JAPAN)","volume":"87","author":"T Muramatsu","year":"2023","journal-title":"Circ J"},{"issue":"16","key":"pone.0325663.ref016","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1817083","article-title":"Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation","volume":"380","author":"RD Lopes","year":"2019","journal-title":"N Engl J Med"},{"issue":"4","key":"pone.0325663.ref017","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1253\/circj.CJ-09-0982","article-title":"Basic principles of platelet biology and clinical implications","volume":"74","author":"DJ Angiolillo","year":"2010","journal-title":"Circ J"},{"issue":"11","key":"pone.0325663.ref018","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"L Wallentin","year":"2009","journal-title":"N Engl J Med"},{"issue":"19","key":"pone.0325663.ref019","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1016\/j.jacc.2007.07.053","article-title":"Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial","volume":"50","author":"CP Cannon","year":"2007","journal-title":"J Am Coll Cardiol"},{"issue":"23","key":"pone.0325663.ref020","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1093\/eurheartj\/ehr422","article-title":"Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial","volume":"32","author":"RC Becker","year":"2011","journal-title":"Eur Heart J"},{"issue":"36","key":"pone.0325663.ref021","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","article-title":"2024 ESC Guidelines for the management of chronic coronary syndromes","volume":"45","author":"C Vrints","year":"2024","journal-title":"Eur Heart J"},{"issue":"36","key":"pone.0325663.ref022","first-page":"3415","article-title":"ESC Guidelines for the management of chronic coronary syndromes: Developed by the task force for the management of chronic coronary syndromes of the European Society of Cardiology (ESC) Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS","volume":"45","author":"C Vrints","year":"2024","journal-title":"). Eur Heart J"},{"issue":"9","key":"pone.0325663.ref023","doi-asserted-by":"crossref","DOI":"10.1161\/CIR.0000000000001168","article-title":"2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines","volume":"148","author":"SS Virani","year":"2023","journal-title":"Circulation"},{"issue":"1","key":"pone.0325663.ref024","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1186\/s12916-023-02969-6","article-title":"Why estimands are needed to define treatment effects in clinical trials","volume":"21","author":"ON Keene","year":"2023","journal-title":"BMC Med"},{"issue":"10151","key":"pone.0325663.ref025","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S0140-6736(18)31858-0","article-title":"Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial","volume":"392","author":"P Vranckx","year":"2018","journal-title":"Lancet"},{"issue":"24","key":"pone.0325663.ref026","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1001\/jama.2019.8146","article-title":"Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: the SMART-CHOICE randomized clinical trial","volume":"321","author":"J-Y Hahn","year":"2019","journal-title":"JAMA"},{"issue":"10456","key":"pone.0325663.ref027","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0140-6736(24)01616-7","article-title":"De-escalation to ticagrelor monotherapy versus 12 months of dual antiplatelet therapy in patients with and without acute coronary syndromes: a systematic review and individual patient-level meta-analysis of randomised trials","volume":"404","author":"M Valgimigli","year":"2024","journal-title":"Lancet"},{"issue":"5","key":"pone.0325663.ref028","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1001\/jamacardio.2024.0133","article-title":"Ticagrelor or clopidogrel monotherapy vs dual antiplatelet therapy after percutaneous coronary intervention: a systematic review and patient-level meta-analysis","volume":"9","author":"M Valgimigli","year":"2024","journal-title":"JAMA Cardiol"},{"issue":"4","key":"pone.0325663.ref029","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1001\/jamacardio.2021.5244","article-title":"Comparison of clopidogrel monotherapy after 1 to 2 months of dual antiplatelet therapy with 12 months of dual antiplatelet therapy in patients with acute coronary syndrome: the STOPDAPT-2 ACS randomized clinical trial","volume":"7","author":"H Watanabe","year":"2022","journal-title":"JAMA Cardiol"},{"issue":"2","key":"pone.0325663.ref030","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jacc.2023.04.051","article-title":"P2Y(12) inhibitor or aspirin monotherapy for secondary prevention of coronary events","volume":"82","author":"F Gragnano","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"pone.0325663.ref031","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1161\/CIRCULATIONAHA.120.046786","article-title":"Comparative efficacy and safety of Oral P2Y12 inhibitors in acute coronary syndrome: network meta-analysis of 52 816 patients from 12 randomized trials","volume":"142","author":"EP Navarese","year":"2020","journal-title":"Circulation"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0325663","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T17:36:46Z","timestamp":1752687406000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0325663"}},"subtitle":[],"editor":[{"given":"Elisabetta","family":"Ricottini","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,7,16]]},"references-count":31,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7,16]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0325663","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,16]]}}}